Department of Pathology
Akira Ainai has not added Biography.
If you are Akira Ainai and would like to personalize this page please email our Author Liaison for assistance.
Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses.
Therapeutics and clinical risk management Feb, 2009 | Pubmed ID: 19436601
PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
Vaccine Oct, 2009 | Pubmed ID: 19840660
Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Journal of medical virology Jan, 2010 | Pubmed ID: 19950232
The first autopsy case of pandemic influenza (A/H1N1pdm) virus infection in Japan: detection of a high copy number of the virus in type II alveolar epithelial cells by pathological and virological examination.
Japanese journal of infectious diseases Jan, 2010 | Pubmed ID: 20093768
Characterization of quasispecies of pandemic 2009 influenza A virus (A/H1N1/2009) by de novo sequencing using a next-generation DNA sequencer.
PloS one Apr, 2010 | Pubmed ID: 20428231
Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus.
Journal of medical virology Oct, 2010 | Pubmed ID: 20827774
Cross-protective immunity against influenza virus infections induced by intranasal vaccination together with a TLR3-mucosal adjuvant.
Human vaccines Jan-Feb, 2011 | Pubmed ID: 21321485
A novel function of the N-terminal domain of PA in assembly of influenza A virus RNA polymerase.
Biochemical and biophysical research communications Nov, 2011 | Pubmed ID: 22001919
Outer membrane vesicles of Porphyromonas gingivalis elicit a mucosal immune response.
PloS one , 2011 | Pubmed ID: 22022548
Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine.
Journal of medical virology Feb, 2012 | Pubmed ID: 22170556
Mucosal IgA responses in influenza virus infections; thoughts for vaccine design.
Vaccine Aug, 2012 | Pubmed ID: 22835738
The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses.
Journal of virology May, 2014 | Pubmed ID: 24600012
Combatting infectious diseases; nanotechnology as a platform for rational vaccine design.
Advanced drug delivery reviews Jul, 2014 | Pubmed ID: 24862579
Cytokine profile of bronchoalveolar lavage fluid from a mouse model of bronchial asthma during seasonal H1N1 infection.
Cytokine Oct, 2014 | Pubmed ID: 24998935
Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus.
Proceedings of the National Academy of Sciences of the United States of America Jun, 2015 | Pubmed ID: 26056267
Host Adaptation and the Alteration of Viral Properties of the First Influenza A/H1N1pdm09 Virus Isolated in Japan.
PloS one , 2015 | Pubmed ID: 26079133
Protective antibody responses against A(H1N1)pdm09 primed by infection and recalled by intranasal vaccination.
Vaccine Nov, 2015 | Pubmed ID: 26432916
The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine.
Vaccine Feb, 2016 | Pubmed ID: 26802605
Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Japanese journal of infectious diseases , 2016 | Pubmed ID: 27212584
Impacts of allergic airway inflammation on lung pathology in a mouse model of influenza A virus infection.
PloS one , 2017 | Pubmed ID: 28245238
Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate.
Viral immunology Jul/Aug, 2017 | Pubmed ID: 28650274
Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus.
Vaccine 09, 2017 | Pubmed ID: 28780981
Pulmonary inflammation and cytokine dynamics of bronchoalveolar lavage fluid from a mouse model of bronchial asthma during A(H1N1)pdm09 influenza infection.
Scientific reports 08, 2017 | Pubmed ID: 28831046
The road to a more effective influenza vaccine: Up to date studies and future prospects.
Vaccine 09, 2017 | Pubmed ID: 28866292
cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue.
Medical sciences (Basel, Switzerland) Dec, 2017 | Pubmed ID: 29258267
Neutralizing Antibodies Induced by Gene-Based Hydrodynamic Injection Have a Therapeutic Effect in Lethal Influenza Infection.
Frontiers in immunology , 2018 | Pubmed ID: 29416543
IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.
Human vaccines & immunotherapeutics 06, 2018 | Pubmed ID: 29425074
Application of HTLV-1 tax transgenic mice for therapeutic intervention.
Advances in biological regulation May, 2018 | Pubmed ID: 29588208
Tuberculous pneumonia-induced severe ARDS complicated with DIC in a female child: a case of successful treatment.
BMC infectious diseases 07, 2018 | Pubmed ID: 29970013
Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics.
Expert review of vaccines 08, 2018 | Pubmed ID: 30092690
IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody.
PLoS pathogens 01, 2019 | Pubmed ID: 30605488
Lin Sun1,
Naoko Kono2,
Hiroyuki Toh3,
Hanbing Xue1,
Kaori Sano4,5,
Tadaki Suzuki4,
Akira Ainai4,
Yasuko Orba6,
Junya Yamagishi7,8,
Hideki Hasegawa4,5,
Yoshimasa Takahashi9,
Shigeyuki Itamura2,
Kazuo Ohnishi9,10
1Graduate School of Life and Environmental Sciences, University of Tsukuba,
2Center for Influenza Virus Research, National Institute of Infectious Diseases,
3School of Science and Technology, Kwansei Gakuin University,
4Department of Pathology, National Institute of Infectious Diseases,
5Division of Infectious Diseases Pathology, Department of Global Infectious Diseases, Tohoku University Graduate School of Medicine,
6Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University,
7Division of Collaboration and Education, Research Center for Zoonosis Control, Hokkaido University,
8Global Station for Zoonosis Control, GI-CoRE, Hokkaido University,
9Department of Immunology, National Institute of Infectious Diseases,
10Faculty of Life and Environmental Sciences, University of Tsukuba
ÜBER JoVE
Copyright © 2024 MyJoVE Corporation. Alle Rechte vorbehalten